Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nuwellis Inc (NUWE)

Nuwellis Inc (NUWE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,374
  • Shares Outstanding, K 4,374
  • Annual Sales, $ 8,860 K
  • Annual Income, $ -20,210 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.32
  • Price/Sales 0.50
  • Price/Cash Flow N/A
  • Price/Book 0.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.36
  • Number of Estimates 1
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -78.32
  • Growth Rate Est. (year over year) +99.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9237 +8.26%
on 12/19/24
1.4500 -31.03%
on 11/27/24
-0.3000 (-23.08%)
since 11/20/24
3-Month
0.9237 +8.26%
on 12/19/24
4.1900 -76.13%
on 11/04/24
-0.2600 (-20.63%)
since 09/20/24
52-Week
0.9237 +8.26%
on 12/19/24
30.1000 -96.68%
on 01/04/24
-17.2700 (-94.53%)
since 12/20/23

Most Recent Stories

More News
Nuwellis, Inc. Regains Compliance with Nasdaq's Minimum Bid Price and Equity Requirements

Nuwellis, Inc. regains compliance with Nasdaq’s bid price and equity requirements, continuing to trade under symbol "NUWE".Quiver AI SummaryNuwellis, Inc. announced that it has regained compliance with...

NUWE : 1.0000 (-0.99%)
Nuwellis Regains Compliance with Nasdaq Listing Requirements

NUWE : 1.0000 (-0.99%)
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

NUWE : 1.0000 (-0.99%)
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

NUWE : 1.0000 (-0.99%)
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

NUWE : 1.0000 (-0.99%)
Nuwellis Announces Preliminary Results for Third Quarter of 2024

NUWE : 1.0000 (-0.99%)
Nuwellis Welcomes University of Iowa Health Care Stead Family Children’s Hospital as Newest Pediatric Customer

NUWE : 1.0000 (-0.99%)
Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

NUWE : 1.0000 (-0.99%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END

SILO : 0.8780 (+5.16%)
BXRX : 0.0218 (+7.39%)
HOTH : 0.8100 (+5.21%)
KALA : 5.92 (-1.33%)
NUWE : 1.0000 (-0.99%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...

SILO : 0.8780 (+5.16%)
BXRX : 0.0218 (+7.39%)
HOTH : 0.8100 (+5.21%)
KALA : 5.92 (-1.33%)
NUWE : 1.0000 (-0.99%)

Business Summary

Nuwellis Inc. is a medical device company. It is focused on developing, manufacturing and commercializing the Aquadex SmartFlow(R) System for ultrafiltration therapy. Nuwellis Inc., formerly known as CHF Solutions, is headquartered in Minneapolis, Minn.

See More

Key Turning Points

3rd Resistance Point 1.1167
2nd Resistance Point 1.0933
1st Resistance Point 1.0467
Last Price 1.0000
1st Support Level 0.9767
2nd Support Level 0.9533
3rd Support Level 0.9067

See More

52-Week High 30.1000
Fibonacci 61.8% 18.9547
Fibonacci 50% 15.5119
Fibonacci 38.2% 12.0690
Last Price 1.0000
52-Week Low 0.9237

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar